Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670268 | 0.81 | LOX (0.37) | ALDH1A1HSD17B10TDP1KDM4EPTGS2 | |
| SCHEMBL21028001 | 0.78 | PTGDR2 (0.41) | PTGDR2ALDH1A1TDP1 | |
| SCHEMBL21186599 | 0.74 | PTGDR2 (0.46) | PTGDR2 | |
| SCHEMBL21032174 | 0.71 | ALDH1A1 (0.33) | ALDH1A1HSD17B10TDP1KDM4EPTGS2 | |
| SCHEMBL21186601 | 0.71 | PDK2 (0.44) | PTGDR2ALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL21028030 | 0.68 | CA2 (0.51) | PTGDR2ALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL21028294 | 0.68 | CA1 (0.40) | PTGDR2ALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL21032481 | 0.68 | CCR1 (0.34) | — | |
| SCHEMBL24133700 | 0.66 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TDP1KDM4EPTGS2 | |
| SCHEMBL10368722 | 0.66 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TDP1KDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| EP-3489233-B1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-11034681-B2 | Crystal form of indole derivative and preparation method and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. | 2021-06-15 | — | — | US | disclosed |
| EP-3741754-A1 | CRYSTAL FORM OF INDOLE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347040-A1 | CRYSTAL FORM OF INDOLE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| WO-2019141241-A1 | CRYSTAL FORM OF INDOLE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2019-07-25 | — | — | WO | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034681-B2 | Crystal form of indole derivative and preparation method and use thereof | HRH1, HRH2, MC2R | PTGDR2 77/4885ALDH1A1 2041/4885HSD17B10 1295/4885 |
| US-20200347040-A1 | CRYSTAL FORM OF INDOLE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | HRH1, HRH2, MC2R | PTGDR2 77/4885ALDH1A1 2041/4885HSD17B10 1295/4885 |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | NR3C2, CRHR2, TPH2 | PTGDR2 97/4885ALDH1A1 1366/4885HSD17B10 901/4885 |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | NR3C2, CRHR2, TPH2 | PTGDR2 97/4885ALDH1A1 1366/4885HSD17B10 901/4885 |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | PTGDR2 152/4885ALDH1A1 3257/4885HSD17B10 440/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | PTGDR2 313/4885ALDH1A1 3139/4885HSD17B10 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.